Quotient Sciences DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Phase I/Clinical Pharmacology

Drug Product Development & Manufacturing Services

Clinical Pharmacology Services

First-in-Human (FIH) Trials to Proof of Concept (POC)

Scalable Drug Product Manufacturing

Translational Pharmaceutics® for first-in-human studies

Inhaled Product Development

Aseptic Development and Manufacturing

Global Formulation Development & Manufacturing Capabilities

Pre-formulation and Material Sciences

Drug Substance Synthesis and Manufacturing

Modified-Release Formulation Strategies

First Subjects Dosing with VS-041 a Novel Heart Failure Treatment

14C Human ADME Program for HTD1801

Oxilio & Quotient Announce Regulatory Approval for OXL001

Expansion of Facilities for Translational Pharmaceutics® Programs

Ensysce Biosciences & Quotient Announce a Partnership

Human ADME Studies

Bioanalytical Services

Translational Pharmaceutics®

Formulation Strategies for Poorly Soluble Molecules

Global Formulation Development & Manufacturing Capabilities

Commercial Manufacturing

Clinical Trial Manufacturing

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Corporate Video

Bioanalysis

Clinical Pharmacology

Clinical Trial Manufacturing

Commercial Manufacturing

Data Sciences

Drug Development Consulting

Drug Substance

Formulation Development

Translational Pharmaceutics®

Bioanalytical Services

Candidate Molecule Selection

CDMO Solutions for Orphan & Rare Diseases

Early Development

Late Development

Orphan Drug Programs

What is Bioanalysis? (BioA)

Our Manifesto

Miami Clinical Pharmacology Facility

DATA COMPILATION #PharmaFlow

CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

The contract development and manufacturing organization (CDMO) sector has emerged as a key partner in new drug development. This was evident from the strategic investments, partnerships, and expansions witnessed in the third quarter (Q3) of 2025. Several CDMOs, such as Cohance Lifesciences, Fermion Oy, Axplora, AGC Pharma Chemicals invested in new projects. Others, including Veranova, Aenova, and Biosynth, expanded capacities, while Ofichem strengthened its footprint with the acquisition of Avivia BV. CDMOs like Fareva, Evonik, and Samsung Biologics forged strategic partnerships for growth. During Q3, the sector continued to adopt artificial intelligence (AI). This prompted the US Food and Drug Administration (FDA) to issue guidance that recognizes the increasing use of AI and data analytics in drug development. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Cohance, Veranova invest in bioconjugation suites in US; ChemExpress inks ADC deal Earlier this year, Indian drugmaker Suven Pharmaceuticals Limited merged with leading CDMO Cohance Lifesciences Limited. The merged entity — Cohance Lifesciences — has invested US$ 10 million in a current Good Manufacturing Practice (cGMP) bioconjugation suite at its subsidiary NJ Bio in Princeton, New Jersey. NJ Bio is executing a major program for an existing innovator client with multiple antibody-drug conjugate (ADC) candidates. Cohance also announced an INR 230 million (approximately US$ 2.58 million) investment in a cGMP oligonucleotide facility at its Hyderabad (India) site. Veranova’s Devens (Massachusetts) site successfully passed a routine FDA cGMP surveillance inspection with a “No Action Indicated” (NAI) classification. Earlier, the company had initiated a US$ 50 million investment to expand its ADC and bioconjugate capabilities at its Devens site. This includes a 9,000-square-foot facility expansion with a new process development lab, two additional cGMP suites, and state-of-the-art bioconjugation development and manufacturing capabilities. These initiatives strengthen the site’s highly potent API (HPAPI) and ADC development and manufacturing capabilities. Biosynth has expanded its Berlin facility with a new GMP bioconjugation suite. The expansion supports the company’s manufacturing capabilities in conjugate vaccines, conjugate drugs, activated polyethylene glycol (PEGs), and polymer-based drug delivery excipients. ChemExpress, Mabwell Bioscience, and Insilico Medicine have entered into a strategic partnership to jointly develop a large ADC compound library and advance next-generation ADC candidates. The collaboration combines Mabwell’s antibody and ADC technology, Insilico’s AI-powered drug design platform, and ChemExpress’s expertise in linker-payload chemistry. Together, they aim to build a complete, AI-driven ADC development model that accelerates discovery, optimization, and commercialization. This partnership is expected to enhance R&D efficiency and deliver safer, more effective cancer treatments. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Fermion, Axplora, Aenova increase API manufacturing capacities; ICE Pharma expands India facility Finnish CDMO Fermion Oy has launched a renovation project at its Hanko (Finland) production site to modernize its API manufacturing capabilities. This expansion is part of Fermion's broader strategy to increase production, enhance flexibility in the manufacturing of both existing and future pharmaceutical products, and enable potential contract manufacturing opportunities. German CDMO Axplora has announced a €6.5 million (approximately US$ 7.5 million) investment to expand its API manufacturing capacity at its Vizag site in India. This expansion aims to strengthen both production capabilities and supply chain resilience. India-based Aarti Pharmalabs has inaugurated the first phase of its greenfield manufacturing facility in Gujarat (India). This expansion aims to bolster Aarti's CDMO and contract manufacturing organization (CMO) services, targeting a revenue goal of INR 10 billion (approximately US$ 112 million). Snapdragon Chemistry, which was acquired by Cambrex in 2023, has expanded its Massachusetts facility to better support peptide drug development and manufacturing. With this upgrade, the company can now handle peptide projects from early development through full-scale manufacturing. Italy-headquartered ICE Pharma has expanded its Raichem facility in India. The new facility will enhance the production of ursodeoxycholic acid (UDCA), an API it derives from chicken bile. This expansion increases the site’s raw UDCA output by 120 metric tons annually. Spain-headquartered AGC Pharma Chemicals inaugurated a new advanced manufacturing plant in Barcelona, with an investment of €110 million (approximately US$ 128.3 million). The plant spans 7,500 square meters and integrates cutting-edge technologies to support the entire drug development lifecycle — from R&D to commercial manufacturing. This represents a 30 percent increase in the company’s production capacity and introduces a segment dedicated to HPAPIs. Germany-headquartered Aenova has launched a new hot melt extrusion platform at its Regensburg (Germany) site. This new equipment enables the production of advanced drug formulations, while handling all testing and quality checks in-house. The move strengthens Aenova’s capabilities in developing and manufacturing complex medications. US-based Cytovance Biologics has introduced in-house formulation development services, enhancing its role as a comprehensive partner for biologic drug developers. These services utilize quality-by-design principles to ensure speed, safety, and precision in current and future client programs. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Ofichem acquires Avivia BV; Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands. This acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions across both drug substance and drug product, with a focus on complex formulations. Ofichem has also acquired Meribel Pharma Solutions’ site in Uppsala (Sweden) to strengthen its support for biotech innovators and expand its presence in the Nordic region. Simtra BioPharma Solutions has acquired a 65-acre property near its Bloomington, Indiana (US) facility, adding over 300,000 square feet of potential expansion space. With this site, Simtra now has the flexibility to rapidly expand in the US. German specialty chemicals company Evonik is partnering with German biotech Ethris to develop and commercialize a next-generation lipid nanoparticle (LNP) platform for delivering nucleic acid therapies. Evonik will assist in formulation using Ethris’ SNaP LNP technology. The LNP market alone is projected to grow to US$2.3 billion by 2032. Luxembourg-headquartered Fareva has partnered with Zhaoke Ophthalmology to expand its footprint in China’s pharma market. Zhaoke will act as Fareva’s go-to partner for customers seeking pharmaceutical manufacturing in China. Samsung Biologics has signed a 1.8 trillion won (US$ 1.3 billion) manufacturing agreement with an undisclosed US-based drugmaker. And UK-based eXmoor Pharma has partnered with Anthony Nolan to provide end-to-end services for cell therapy developers. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032. Significantly, about 60 percent of new drug approvals in the US and over 65 percent in Europe now involve CDMO support. The developments outlined above underscore the increasing role CDMOs are playing today in bringing about growth and innovation in the pharmaceutical industry.

Impressions: 3629

CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025.

Impressions: 5460

CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines.

Impressions: 5126

NEWS #PharmaBuzz

Quotient Sciences Extends Mfg Partnership For Ultra-Rare Disease

27 Feb 2026

// PRESS RELEASE

First-in-Human Is Not Just About Safety

09 Feb 2026

// PRESS RELEASE

VP Marlene Leuenberger on CPHI Online A Day in the Life

27 Jan 2026

// PRESS RELEASE

Dr. Andrew Lewis On Speed, Scale And Science In Pandemic Response

20 Jan 2026

// PRESS RELEASE

Dr. Asma Patel contributes to PharmTech

16 Jan 2026

// PRESS RELEASE

John McDermott Contributes to European Pharma Manufacturer

14 Jan 2026

// PRESS RELEASE

Drugs in Development

Services

Discover the service capabilities from this company

Analytical

Discover their expertise for :

Analytical Method Development

01

ANALYTICAL METHOD DEVELOPMENT

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Analytical

Quotient Sciences provides the best analytical support, delivering phase-appropriate method development and validation, candidate screening and drug product analysis.

Category : Analytical Method Development

Sub Category : Method Development and Validation

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Analytical

ANALYTICAL METHOD DEVELOPMENT

Quotient Sciences provides the best analytical support, delivering phase-appropriate method development and validation, candidate screening and drug product analysis.

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Clinical Trials

Discover their expertise for :

Packaging & Logistics

01

STORAGE AND DISTRIBUTION CAPABILITIES

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

Quotient Sciences supports all aspects of drug product supply to support phase I, phase II and phase III clinical studies, including storage and distribution capabilities (ambient, refrigerated and frozen), shipment logistics and supply tracking, etc.

Category : Packaging & Logistics

Sub Category : Storage Solutions

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

STORAGE AND DISTRIBUTION CAPABILITIES

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patient / Investigator Recruitment

01

PATIENT RECRUITMENT FOR CLINICAL TRIALS

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

Quotient Sciences has the experience and expertise to seamlessly deliver the studies with the highest quality service and speed for a complete service, including rapid recruitment, data analysis, medical writing, etc.

Category : Patient / Investigator Recruitment

Sub Category : Patient Recruitment

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

PATIENT RECRUITMENT FOR CLINICAL TRIALS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Clinical Development / Phase IIb-IV

01

BIOAVAILABILITY & BIOEQUIVALENCE STUDIES

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

Quotient Sciences has the experience and expertise to seamlessly deliver several studies involving bioavailability, dose proportionality, relative bioavailability, bioequivalence, food effect, thorough QT (TQT), biosimilars, pharmacodynamics, etc.

Category : Clinical Development / Phase IIb-IV

Sub Category : Bioavailability / Bioequivalence

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

BIOAVAILABILITY & BIOEQUIVALENCE STUDIES

Capabilities
#ServicesBio

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Medical Writing & Language Translation

01

MEDICAL WRITING

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

Quotient Sciences, under medical writing, provides clinical study reports as per the FDA guidance for industry along with related submissions using eCTD specification.

Category : Medical Writing & Language Translation

Sub Category : Overview

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

MEDICAL WRITING

Quotient Sciences, under medical writing, provides clinical study reports as per the FDA guidance for industry along with related submissions using eCTD specification.

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Early Clinical / Phase I-IIa

01

PHASE I CLINICAL PHARMACOLOGY STUDY

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

Quotient Sciences has the experience and expertise to seamlessly deliver phase I clinical pharmacology study with the highest quality service & speed. It provides a complete service, including data management, medical writing, etc.

Category : Early Clinical / Phase I-IIa

Sub Category : Phase I / IIa

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

PHASE I CLINICAL PHARMACOLOGY STUDY

Capabilities
#ServicesBio

02

PHARMACOKINETIC & PHARMACODYNAMIC ASSESS...

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

Quotient Sciences has the experience and expertise to seamlessly deliver several studies involving pharmacokinetic assessments, pharmacodynamics, dose proportionality, bioequivalence, etc.

Category : Early Clinical / Phase I-IIa

Sub Category : Pharmacokinetics / Pharmacodynamics / Pharmacometrics

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Clinical Trials

PHARMACOKINETIC & PHARMACODYNAMIC ASSESSMENTS

Quotient Sciences has the experience and expertise to seamlessly deliver several studies involving pharmacokinetic assessments, pharmacodynamics, dose proportionality, bioequivalence, etc.

Pharmacokinetic & Pharmacodynamic Assessments

Capabilities
#ServicesBio

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Technology / Data / Analytics

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Compliance, Regulatory & Consulting

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Manufacturing

Discover their expertise for :

GMP Manufacturing

01

GMP DRUG SUBSTANCE MANUFACTURING

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : API Manufacturing

Quotient Sciences has facilities that can provide both GMP and non-GMP drug substance manufacturing with the ability to generate quantities in kg per day. Its capability includes 5L GMP and non-GMP process chemistry facilities with full thermal control.

Category : GMP Manufacturing

Sub Category : Overview

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : API Manufacturing

GMP DRUG SUBSTANCE MANUFACTURING

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Continuous Flow Process

01

FLOW CHEMISTRY

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : API Manufacturing

Quotient Sciences has more than 40 years of experience in synthetic organic chemistry coupled with extensive expertise in flow chemistry, synthetic biology and biocatalysis.

Category : Continuous Flow Process

Sub Category : Overview

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : API Manufacturing

FLOW CHEMISTRY

Quotient Sciences has more than 40 years of experience in synthetic organic chemistry coupled with extensive expertise in flow chemistry, synthetic biology and biocatalysis.

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drug Product Manufacturing

Discover their expertise for :

Powder

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Suspension

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Compounding

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Injectable / Parenteral

01

CLINICAL SUPPLY OF PARENTERALS

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Drug Product Manufacturing

Quotient Sciences offers clinical trial manufacturing services for parenteral dosage forms [intravenous (IV), intramuscular (IM) and subcutaneous (SC)].

Category : Injectable / Parenteral

Sub Category : Clinical Supply

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Drug Product Manufacturing

CLINICAL SUPPLY OF PARENTERALS

Quotient Sciences offers clinical trial manufacturing services for parenteral dosage forms [intravenous (IV), intramuscular (IM) and subcutaneous (SC)].

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Nasal

01

NASAL SPRAY CLINICAL MANUFACTURING

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Drug Product Manufacturing

Quotient Sciences has extensive expertise and capabilities for nasal and pulmonary deliveries, including clinical manufacturing, supply (phase I-III) and clinical pharmacology assessments.

Category : Nasal

Sub Category : Clinical Supply

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Drug Product Manufacturing

NASAL SPRAY CLINICAL MANUFACTURING

Quotient Sciences has extensive expertise and capabilities for nasal and pulmonary deliveries, including clinical manufacturing, supply (phase I-III) and clinical pharmacology assessments.

02

INHALED DRUG PRODUCT MANUFACTURING

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Drug Product Manufacturing

Quotient Sciences has a track record of 30 years in the development and manufacturing of inhaled drug products. It has experience across a range of drug delivery platforms, including dry powder inhalers (DPIs) and solutions or suspensions for inhalation.

Category : Nasal

Sub Category : Inhalation

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Drug Product Manufacturing

INHALED DRUG PRODUCT MANUFACTURING

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Liquid

01

CONTRACT MANUFACTURING FOR LIQUIDS

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Drug Product Manufacturing

Quotient Sciences offers commercial product manufacturing of oral liquid dosage forms, including solutions and suspensions. Its commercial batch size capabilities include up to 350L for liquid formats using an automated filling line.

Category : Liquid

Sub Category : Overview

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Drug Product Manufacturing

CONTRACT MANUFACTURING FOR LIQUIDS

02

CLINICAL TRIAL MANUFACTURING FOR LIQUIDS

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Drug Product Manufacturing

Quotient Sciences offers clinical trial manufacturing services for various oral dosage forms, including liquid and solid forms. It also provides clinical testing services for drug products including solutions, suspensions, solubilized formulations, etc.

Category : Liquid

Sub Category : Clinical Supply

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : Drug Product Manufacturing

CLINICAL TRIAL MANUFACTURING FOR LIQUIDS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Capsule

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Solution

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Tablet

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API & Drug Product Development

Discover their expertise for :

API Development

01

BIOCATALYSIS

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : API & Drug Product Development

Quotient Sciences is a CDMO with more than 40 years of experience in synthetic organic chemistry coupled with biocatalysis, flow chemistry and synthetic biology.

Category : API Development

Sub Category : Biocatalysis

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : API & Drug Product Development

BIOCATALYSIS

Quotient Sciences is a CDMO with more than 40 years of experience in synthetic organic chemistry coupled with biocatalysis, flow chemistry and synthetic biology.

02

API PROCESS RESEARCH & DEVELOPMENT

United Kingdom

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : API & Drug Product Development

Quotient Sciences offers services including process research and development. It supports all aspects of drug substance development, selecting and developing optimum synthetic routes for drug substance manufacturing.

Category : API Development

Sub Category : Process Development & Optimization

Quotient Sciences- Molecule to Cure. Fast.

Pharma Service : API & Drug Product Development

API PROCESS RESEARCH & DEVELOPMENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Preformulation & Material Science

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Formulation Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Packaging

Discover their expertise for :

Clinical Services

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KEY SERVICES

TOP RANKED SUPPLIER FOR:

Formulation Development Services of Capsules

Suspension Design & Development Services

Formulation Development Services of Tablets

Inspections and registrations

Check the inspections & registration from this company

FDA

01 FDA Audited

USA

District Decision : Voluntary Action Indicated

Inspection End Date : 2025-09-17

City : Boothwyn

State :

Country/Area : U.S.A

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2025-09-17

Product
Web Link

02 FDA Audited

USA

District Decision : Voluntary Action Indicated

Inspection End Date : 2024-08-29

City : Alnwick

State :

Country/Area : United Kingdom

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2024-08-29

Product
Web Link

03 FDA Audited

USA

District Decision : No Action Indicated

Inspection End Date : 2023-07-28

City : Alnwick

State :

Country/Area : United Kingdom

Zip :

District :

Center :

Project Area : Bioresearch Monitoring

District Decision : No Action Indicated

Inspection End Date : 2023-07-28

Product
Web Link

04 FDA Audited

USA

District Decision : Voluntary Action Indicated

Inspection End Date : 2022-12-22

City : Boothwyn

State :

Country/Area : U.S.A

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2022-12-22

Product
Web Link

05 FDA Audited

USA

District Decision : Voluntary Action Indicated

Inspection End Date : 2019-06-21

City : Alnwick

State :

Country/Area : United Kingdom

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2019-06-21

Product
Web Link

06 FDA Audited

USA

District Decision : No Action Indicated

Inspection End Date : 2019-05-30

City : Miami

State :

Country/Area : U.S.A

Zip :

District :

Center :

Project Area : Bioresearch Monitoring

District Decision : No Action Indicated

Inspection End Date : 2019-05-30

Product
Web Link

07 FDA Audited

USA

District Decision : Voluntary Action Indicated

Inspection End Date : 2017-11-06

City : Boothwyn

State :

Country/Area : U.S.A

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2017-11-06

Product
Web Link

08 FDA Audited

USA

District Decision : Voluntary Action Indicated

Inspection End Date : 2017-02-14

City : Alnwick

State :

Country/Area : United Kingdom

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2017-02-14

Product
Web Link

09 FDA Audited

USA

District Decision : Voluntary Action Indicated

Inspection End Date : 2015-11-02

City : Boothwyn

State :

Country/Area : U.S.A

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2015-11-02

Product
Web Link

10 FDA Audited

USA

District Decision : No Action Indicated

Inspection End Date : 2015-02-10

City : Alnwick

State :

Country/Area : United Kingdom

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : No Action Indicated

Inspection End Date : 2015-02-10

Product
Web Link